ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Observational
- Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOlder (≥50 years of age [YoA]) and immunocompromised adults are at higher risk of herpes zoster (HZ). Those with comorbidities are also at increased risk, however, recent US evidence is lacking, especially among 18-49 YoA.
methodsThis US retrospective cohort study (2015-2022, Merative MarketScan Commercial and Medicare Supplemental) compared HZ incidence rates (IRs) in younger immunocompetent adults (18-49 YoA) with comorbidities (asthma, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD], depression, diabetes, stress, and trauma) versus immunocompetent adults 50-59 YoA without comorbidities. Adjusted HZ IR ratios (aIRRs) versus 50-59 YoA adults were compared using a predetermined 0.62 non-inferiority margin for the aIRR 95% confidence interval lower limit (95% CI LL). aIRRs were classified as comparable (aIRR 95% CI LL > 0.62 and ≤1.0), significantly higher (aIRR 95% CI LL > 1.0), or inconclusive (any other result). HZ case: diagnostic code B02.2x plus oral antiviral ±7 days. Sensitivity analyses investigated HZ IRs by number of comorbid conditions (1, 2, or ≥3).
resultsHZ IRs were significantly higher (aIRR 95% CI LL > 1.0) from 30 to 39 YoA (aIRR; 95% CI) in asthma (1.19; 1.10-1.29), COPD (1.31; 1.22-1.40), depression (1.31; 1.22-1.40), diabetes (1.18; 1.06-1.32), stress (1.28; 1.11-1.47), and trauma (1.25; 1.17-1.34) populations than immunocompetent 50-59 YoA and from 50 to 59 YoA in CKD (1.50; 1.28-1.77). In sensitivity analyses, HZ IR appeared to increase with more comorbid conditions and age.
conclusionsThe study found that younger adults (30+ YoA) with certain comorbidities have a higher HZ risk than immunocompetent 50-59 YoA adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.